From the FDA Drug Label
Rasagiline tablets are a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson's disease
The use of Rasagiline is for the treatment of Parkinson's disease. It acts as a monoamine oxidase B (MAO-B) inhibitor to increase the levels of dopamine in the brain, which helps to mediate its beneficial effects in patients with Parkinson's disease 1 1.
From the Research
Use of Rasagiline
Rasagiline is a selective and irreversible monoamine oxidase B inhibitor used in the treatment of Parkinson's disease. The primary use of rasagiline includes:
- Improving motor symptoms in patients with Parkinson's disease 2, 3, 4, 5, 6
- Preventing motor complications in Parkinson's disease 2, 3, 4, 5, 6
- Reducing "off" time in patients with advanced Parkinson's disease 2, 3, 4, 5, 6
Efficacy of Rasagiline
The efficacy of rasagiline has been demonstrated in several clinical trials, including:
- Monotherapy in early Parkinson's disease, where rasagiline 1mg/day reduced the Unified Parkinson Disease Rating Scale (UPDRS) score [-3.06 (95% CI -3.81 to -2.31, p<0.00001)] 2
- Adjunctive treatment to levodopa, where 1mg/day of rasagiline reduced "off" time [-0.93h (95% CI -1.17 to -0.69, p<0.00001)] 2
- Reducing wearing-off time, levodopa dosage, UPDRS/MDS-UPDRS II and III scores, and Parkinson's Disease Questionnaire (PDQ-39) summary index score in patients with Parkinson's disease experiencing motor fluctuations 5
Safety and Tolerability
Rasagiline has been shown to be well tolerated and safe in clinical trials, with: